Clinical trials: Functional Insufficiency
Hepatic Insufficiency (MeSH ID: D048550)
A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function
This study is a single-center, non-randomized, open-label, parallel, single-dose study to evaluate the PK profile and safety of MY008211A Tablets in subjects with hepatic impairment.
- Trial name
- NCT07625618
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Renal Impairment, Healthy
A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010
This Study will evaluate the effects of renal function on pharmacokinetics and safety of DA-8010
- Trial name
- NCT05812417
- Testing
- DA-8010
- Where
- South Korea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Coronary Artery Bypass Surgery, Coronary Heart Disease
An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
The purpose of this study is to assess whether nesiritide compared to placebo when given with standard of care therapies, helps preserve kidney function in heart failure (HF) patients undergoing heart bypass graft surgery that…
- Conditions
- Coronary Artery Bypass Surgery, Coronary Heart Disease, Coronary Artery Bypass Grafting, Cardiopulmonary Bypass
- Trial name
- NCT00530361
- Testing
- Nesiritide
- Sponsor
- Scios, Inc.
Mitral Stenosis With Insufficiency, Functional Mitral Regurgitation
AVJ-514 Japan Trial
The objective of the study is to confirm the reproducibility of the evidence of safety and efficacy of AVJ-514 System technology in Japanese subjects who have been deemed difficult for mitral valve surgery by the local site heart…
- Conditions
- Mitral Stenosis With Insufficiency, Functional Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence
- Trial name
- NCT02520310
- Testing
- AVJ-514
- Where
- 6 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Abbott Medical Devices
Renal Impairment
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
The purpose of this study is to assess the PK, tolerability, and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.
- Trial name
- NCT06708520
- Testing
- Rupatadine
- Where
- 7 sites in Portugal, Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Noucor Health S.A.
Chronic Renal Failure
Initiative for Patient Outcomes in Dialysis - Peritoneal Dialysis (PD) (IPOD-PD Study)
The aim of the study is to asses the hydration status of incident peritoneal dialysis (PD) patients and its evolution over a period of four years, independent of the PD treatment modality (APD or CAPD) and the PD solution type.
- Trial name
- IPOD-PD (NCT01285726)
- Testing
- Non-interventional study
- Where
- 134 sites in Austria, Belgium and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hepatic Insufficiency, Neoplasms
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
- Trial name
- NCT05209295
- Testing
- Onureg
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 2 people
- Sponsor
- Bristol-Myers Squibb
Hepatic Insufficiency
Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.
- Trial name
- NCT00692341
- Testing
- AG-013736
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Renal Failure
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
To study the pharmacokinetics and safety of naproxcinod in patients with impaired renal function
- Trial name
- HCT3012-X-106 (NCT00674856)
- Testing
- naproxcinod
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NicOx
Schizophrenia, Psychiatric Disorders
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
- Trial name
- NCT01289080
- Testing
- OPC-34712
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Kidney Transplantation
A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.
The purpose of this study is to compare the effect of two anti-rejection therapy regimens on kidney function in kidney transplant recipients.
- Trial name
- ADHERE (NCT01363752)
- Testing
- Advagraf, Mycophenolate Mofetil, Sirolimus
- Where
- 58 sites in Australia, Austria and 15 more
- Volunteers
- 853 people
- Sponsor
- Astellas Pharma Inc
Severe Renal Impairment
A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine
The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.
- Trial name
- NCT01675973
- Testing
- RANEXA
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Renal Impairment, Renal Insufficiency
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
This study is being conducted in order to assess the need for dose adjustment for elafibranor in participants with renal impairment.
- Conditions
- Renal Impairment, Renal Insufficiency, Kidney Diseases, Pharmacokinetics
- Trial name
- NCT03844555
- Testing
- Elafibranor
- Where
- 2 sites in France, Romania
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Genfit
Degenerative Mitral Valve Disease, Mitral Regurgitation
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve…
- Conditions
- Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
- Trial name
- CLASP IID/IIF (NCT03706833)
- Testing
- Edwards PASCAL System, Abbott Mitraclip System
- Where
- 81 sites in United States, Canada and 2 more
- Volunteers
- 1,247 people
- Sponsor
- Edwards Lifesciences
Diabetes Mellitus, Type 2, Renal Insufficiency
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who have reduced kidney function.
- Trial name
- NCT01064414
- Testing
- Canagliflozin
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 272 people
- Sponsor
- Janssen Research & Development, LLC
Renal Insufficiency, End Stage Renal Disease
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT03482024
- Testing
- Tirzepatide
- Where
- 4 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Renal Impairment
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
This is two stage design, open-label, multi-center, non-randomized trial evaluating the PK of a single, subcutaneous dose of 10 mg glepaglutide in subjects with varying degrees of renal function.
- Trial name
- NCT04178447
- Testing
- Glepaglutide
- Where
- 3 sites in Hungary, Poland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Patients With Impaired Renal Function and Haemodialysis
ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis
The objective of this study is to evaluate the pharmacokinetics and safety of ASP8825 in patients with impaired renal function and haemodialysis.
- Trial name
- NCT02629224
- Testing
- ASP8825
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Astellas Pharma Inc
Hepatic Insufficiency
A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function
This study is designed to evaluate how CP-690,550 is handled by the body in healthy volunteers who have mild and moderate hepatic impairment compared to healthy volunteers with normal hepatic function.
- Trial name
- NCT00969813
- Testing
- CP-690,550
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Mitral Regurgitation, Mitral Insufficiency
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP).
- Conditions
- Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases
- Trial name
- SUMMIT (NCT03433274)
- Testing
- Tendyne Mitral Valve System, MitraClip System
- Where
- 78 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Abbott Medical Devices